Pre-CTA

News

Entropy signs Pre-CTA with UCSF to develop a US-based Phase 2 trial comparing IV psilocin treatment directly against escitalopram (Lexapro) in MDD.

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.